复星医药今年一季度归母净利润增长25.42%

新京报
Yesterday

4月29日,复星医药公布2025年第一季度业绩报告。报告期内,复星医药实现营业收入94.20亿元,同比下滑7.26%;归母净利润7.65亿元,同比增长25.42%;经营活动现金流10.56亿元。营收下滑主要是受药品集采续标及部分地方药品集采开展的影响。报告期内,复星医药持续推进非战略非核心资产的退出和整合,持续推进资产结构优化,加速现金回流。  今年以来,复星医药多项创新成果持续兑现。创新研发方面...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10